Abstract
Multiple myeloma (MM) is characterized by the impaired osteogenic differentiation of human mesenchymal stromal cells (hMSCs). Canonical Wnt signaling is critical for the regulation of bone formation, however, recent evidence suggests that the non-canonical Wnt agonist Wnt5a stimulates human osteoblastogenesis through its co-receptor Ror2. The effects of MM cells on non-canonical Wnt signaling and the effect of the activation of this pathway on MM-induced osteoblast exhaustion are not known and were investigated in this study. We found that the osteogenic differentiation of bone marrow hMSCs toward osteoprogenitor cells (PreOB) significantly increased Ror2 expression, and that MM cells inhibit Ror2 expression by PreOB in co-culture by inhibiting the non-canonical Wnt5a signaling. The activation of the non-canonical Wnt pathway in hMSCs by means of Wnt5a treatment and the overexpression of Wnt5 or Ror2 by lentiviral vectors increased the osteogenic differentiation of hMSCs and blunted the inhibitory effect of MM in co-culture. Consistently, Wnt5a inhibition by specific small interfering RNA reduced the hMSC expression of osteogenic markers. Our findings demonstrate that the Wnt5a/Ror2 pathway is involved in the pathophysiology of MM-induced bone disease and that the activation of the non-canonical Wnt5a/Ror2 pathway in hMSCs increases osteogenic differentiation and may counterbalance the inhibitory effect of MM cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Raje N, Roodman GD . Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278–1286.
Giuliani N, Rizzoli V, Roodman GD . Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992–3996.
Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472–2483.
Giuliani N, Rizzoli V . Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma 2007; 48: 2323–2329.
Westendorf JJ, Kahler RA, Schroeder TM . Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19–39.
Krishnan V, Bryant HU, MacDougald OA . Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202–1209.
Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ . Update on Wnt signaling in bone cell biology and bone disease. Gene 2012; 492: 1–18.
Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008; 111: 2833–2842.
Qiang YW, Shaughnessy JD, Yaccoby S . Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008; 112: 374–381.
Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371–379.
Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192–199.
Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111.
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494.
Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009; 113: 517–525.
Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665–7674.
Boland GM, Perkins G, Hall DJ, Tuan RS . Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004; 93: 1210–1230.
De Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C . Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 2004; 34: 818–826.
Komiya Y, Habas R . Wnt signal transduction pathways. Organogenesis 2008; 4: 68–75.
Kühl M . Non-canonical Wnt signaling in Xenopus: regulation of axis formation and gastrulation. Semin Cell Dev Biol 2002; 13: 243–249.
Liu F, Kohlmeier S, Wang CY . Wnt signaling and skeletal development. Cell Signal 2008; 20: 999–1009.
Baksh D, Boland GM, Tuan RS . Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 2007; 101: 1109–1124.
Baksh D, Tuan RS . Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 2007; 212: 817–826.
Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 2007; 282: 30938–30948.
Santos A, Bakker AD, de Blieck-Hogervorst JM, Klein-Nulend J . WNT5A induces osteogenic differentiation of human adipose stem cells via rho-associated kinase ROCK. Cytotherapy 2010; 12: 924–932.
Minami Y, Oishi I, Endo M, Nishita M . Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn 2010; 239: 1–15.
Liu Y, Rubin B, Bodine PV, Billiard J . Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 2008; 105: 497–502.
Billiard J, Way DS, Seestaller-Wehr LM, Moran RA, Mangine A, Bodine PV . The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 2005; 19: 90–101.
Liu Y, Ross JF, Bodine PV, Billiard J . Homodimerization of Ror2 tyrosine kinase receptor induces 14–3–3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. Mol Endocrinol 2007; 21: 3050–3061.
Liu Y, Bhat RA, Seestaller-Wehr LM, Fukayama S, Mangine A, Moran RA et al. The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. Mol Endocrinol 2007; 21: 376–387.
Qiang YW, Chen Y, Hu B, Qiang W, Hueck C, Yaccoby S et al. Secreted frizzled-related protein-3 (sFRP3) is produced by myeloma cells and augments wnt3a-induced differentiation of mesenchymal stem cells and OPG production in osteoblasts. Blood 2011; 118: 808a.
Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005; 11: 880–885.
Penolazzi L, Lisignoli G, Lambertini E, Torreggiani E, Manferdini C, Lolli A et al. Transcription factor decoy against NFATc1 in human primary osteoblasts. Int J Mol Med 2011; 28: 199–206.
D'Souza S, Del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011; 118: 6871–6880.
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160–3165.
Fromigué O, Haÿ E, Barbara A, Marie PJ . Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem 2010; 285: 25251–25258.
Lisignoli G, Toneguzzi S, Piacentini A, Cristino S, Grassi F, Cavallo C et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003; 194: 71–79.
Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uzé G . Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 2005; 102: 11917–11922.
Rauner M, Stein N, Winzer M, Goettsch C, Zwerina J, Schett G et al. WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 2012; 27: 575–585.
Acknowledgements
This study was supported by grants from the International Myeloma Foundation, the Italian Ministry of Health (Progetti Regione Emilia Romagna), and the Associazione Italiana per la Ricerca sul Cancro (AIRC: NG: IG2099 no. 8530; AN: IG4569 and Special Program Molecular Clinical Oncology 5 per mille no. 9965). We would like to thank Rebecca Silbermann for editing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bolzoni, M., Donofrio, G., Storti, P. et al. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 27, 451–463 (2013). https://doi.org/10.1038/leu.2012.190
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.190
Keywords
This article is cited by
-
The role of wnt signaling in diabetes-induced osteoporosis
Diabetology & Metabolic Syndrome (2023)
-
Noncanonical Wnt5a signaling regulates tendon stem/progenitor cells senescence
Stem Cell Research & Therapy (2021)
-
The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation
Leukemia (2020)
-
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Leukemia (2018)
-
Mechanisms of Altered Bone Remodeling in Multiple Myeloma
Clinical Reviews in Bone and Mineral Metabolism (2017)